+
Site Tour

AV Valves Summit 2024 | Closing of Day 1

F. Maisano, M. Metra, M. Sitges, R. S. Von Bardeleben

FIND OUT MORE ON AV VALVES SUMMIT 2024:

Watch on Demand videos

Related Videos

Navigating the Anatomy | Mitral focus

Case Transmission | Tricuspid focus

TriClip - AVVS 1 year 1 minute Tricuspid - Video

Review the Trends | Tricuspid focus

AV Valves Summit 2024 | Opening of Day 2

PremiClose 2024: Medical therapy or wait

LAAO Summit - Pre-procedural imaging

PCRLV 2021: MR & TR Clip Therapies

EuroPCR 2021: Advancing solutions for tricuspid regurgitation patients

Irie's testimonial

AV VALVES 2023: Staged, Concomitant

AV VALVES 2023: Fast Forward 20 Years

LAAO Summit 2022: Live case: Denmark

TRENDING TOPICS

EACTS 2024 - Novel approaches for Valvular and LVAD therapies

Reconsidering current approaches to valve and LVAD therapies

Early outcomes on Epic Max platfrom

Cleveland clinic (US) experience: Early outcomes and a perspective on porcine vs. bovine

Transfemoral TAVI

Navitor Vision 35 implantation

CONNEXT


HUB
RELATED RESOURCES

EuroEcho 2021: MR Treatment (Evidence)

EuroEcho 2021: Tricuspid regurgitation: The Patient

Clinical insights: LAAO

PCRLV 2021: Transcatheter mitral valve replacement

CONNEXT


LIVE
RELATED EVENTS

AV VALVES 2023: HoloLens Technology

LAAO Summit - Debate: Factor XI inhibitors

Trending Controversies | AV Valves

Review the Trends | Mitral focus

You are about to leave my-connext.com

You are now leaving my-connext.com. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.

The content on this website is intended for healthcare professionals in EMEA with applicable health authority product registrations, excepted those practicing in France as some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011 article 34. Click OK to confirm you are a healthcare professional to proceed.

OK Decline